Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC

Inclusion Criteria: * Age 18 to 80 years * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) * Newly diagnosed, previously untreated stage IIIA-IIIB NSCLC according to the 9th edition TNM staging system * Initially unresectable disease as determined by multidisciplinary team (MDT) assessment * At least 1 measurable intrapulmonary lesion according to RECIST version 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Forced expiratory volume in the first second (FEV1) \> 1.0 L and \> 40% of predicted normal value * Estimated life expectancy of at least 3 months * Adequate organ function * Willingness to provide tumor tissue for pathology, molecular testing, and PD-L1 assessment before enrollment * Women of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab * Men with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab * Ability to understand and willingness to sign a written informed consent form Exclusion Criteria: * Prior local therapy for NSCLC, including radiotherapy or interventional therapy * Known positive driver genomic alterations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and MET exon 14 skipping alterations * Distant organ metastasis * His…